Los Angeles Times - 02.08.2019

C6 FRIDAY, AUGUST 2, 2019 LATIMES.COM/BUSINESS

Yo ur exclusiveguide

to SoCal real estate

listings.

AdvertiseToday

LA Times Classified

(800) 234-4444

LegalNotices

latimes.com/placead

To placeanadcall1.800.234.4444

MARKETPLACE

JOBS ·REAL ESTATE·MORE

Legal Notices

NOTICEOFPETITION

TOADMINISTER

ESTAT EOF:

KuoHsiungChen

19STPB06778

Toal lheirs,beneficiaries,creditors,contingent

creditors,andpersonswhomayotherwis ebeinterested

inthewillorestate ,orboth,of:

KuoHsiungChen

APETITIONFORPROBATEhasbeenfiledbyMing

Yang Leein th eSuperior Court of California, County

ofLosAngeles.

THE PETITION FOR PROBATE requeststhatMing

Yang Leebe appointedaspersonal representativ eto

administertheestateoft hedecedent.

THE PETITION requests authoritytoa dminister the

estate under the Independent Administration of Estates

Act.(This authority will allow the personal

representative to take manyactions wi thout obtaining

court approval.Before taking certain veryimportant

actions, however, the personal representative will be

requiredtogivenoticetointerestedpersonsunlessthey

have waived notice or consentedtothe proposed

action.) The independent administration authoritywill

begrantedunlessanin terestedpersonfilesano bjection

to the petition and shows good cause why the court

shouldnotgranttheauthority.

AHEARING onthepetition will be held onAugust

21,2019at8:30a.m.inDept.2Dlocatedat

111NorthHillStreet,

LosAngeles,CA90012

IF YOU OBJECT to the granting of the petition, you

should appear at the hearing and state your objections

or file written objections with the court before the

hearing. Yourappearancemaybeinp erso norbyy our

attorney.

IF YOU AREACREDITOR or contingentcreditor of

the decedent, you must file your claimwith th ecourt

and mai lacopytothe personal representative

appointe dbythecour twithinthe laterofeither(1)four

months from thedate of first issuance of letters to a

general personal representative,asdefined insection

58(b) of the CaliforniaProbate Code,or( 2) 60 days

from the date ofmailingorpersonal deliverytoyou of

anotice under section 9052 of the CaliforniaProbate

Code.OtherCaliforniastatutesan dlegalauthoritymay

affec tyour rights asacreditor. You may want to

consultwith an attorneyknowledgeableinCalifornia

law.

YOUMAY EXAMINE the filekept by th ecourt. If

you are apersonintereste dinthe estate, youmay file

with th ecourt aRequest fo rSpecial Notice(form DE-

154)ofthefilingofaninventoryandappraisalofestate

assets or of any petition or account as provided in

ProbateCode section 1250.AReques tfor Special

Noticeformisavailablefromthecourtclerk.

Attorneyforpetitioner:

ErickR.Altona

960CanterburyPlace,Suite#300

Escondido,CA92025

(760)743-1201

PublishedLosAngelesTimes

August2,9,&162019

Legal Notices

LEGALNOTICE

PLEASE TAKENOTICEthatapublicauction

pursuant to Section 9-610 of the Uniform Commercial

Code will be conducted by The Credit Junction (the

“Secured Party”)ofthe fil mlibrary assetsofBellum

Entertainmentavailable at Bellum’s offices andat

Bonded Services,amedia storagefacility. THIS IS A

SUPPLEMENTAL NOTICE THAT RESCHEDULES

THE DATEOFT HE AUCTION AND EXTENDS

OTHERRELEVANTDEADLINES. The film library

assetsrelatetotelevisio nprogramsandepisodesacross

variousgenressuchaseducationalandinformational

and crime and thriller, and include materialssuch as

maste rtapes, licensing agreements, distribution

contracts, other associated materials andrelated

intellectual property rights (the “Collateral”).Further

information regarding the Collateral is accessibleina

dataroom (the “Data Room”) to which prospective

bidderswillbegrantedaccessuponexecutionofanon-

disclosure agreement and satisfactory completion of a

diligence questionnaire. Interested partiesshould

review and consider the materialsinthe Dat aRoom

before makingadecision as to whether to bid on the

Collate ral. As the Data Room will be updated with

additional information, prospective bidders should

continue to monitor it until August 21, 2019. The

Collateral is being sold “as is”,without representations

orwar ranties(expressorimplied).

Thenewdateoftheauctionisasfollows:

Date: August22,2019

Time: 8:00a.m.(Pacifictime)

Place:BryanCaveLeightonPaisnerLLP

120Broadway,Suite300

SantaMonica,CA90401

Intereste dparties should contact Thomas Thompson at

Armory Securities, LLCat( 310) 220-6406 or

[email protected] for additional

information regarding the filmlibrary as sets and the

auction process and to obtain copies of the non-

disclosureagreementandadiligencequestionnaire. To

be eligible to participate in the auction interested

partie smust:

(1) by 5:00 p.m. (Pacifictime)onAugust 8,

2019,delivercontactinformationandanexecutedcopy

of the non-disclosure agreement and completed

diligence questionnaire to Armory at the email address

set forth above, with acopy to

[email protected]

(2) by 5:00 p.m. (Pacifictime)onAugust 14,

2019,presenttoArmoryaninitialbidand doc umentary

proof of its financial ability to make such bid free and

clearofthirdpartyclaims

Armory reservesthe right to require additional

documentation onacase-by-casebasis.Armory will

notifyprospectivebidderswhethertheyarequalifiedto

bidattheauctionandareeligibletoconductaphysical

inspection of theCollateral ,which wil lbea vailable

commencing 9:00 a.m. (Pacific time)onAugust 15,

2019andending5:00p.m.(Pacifictime)onAugust21,

2019.

Theassetswillbesoldtooneormorequalifiedbidders

eithe rinlots or in asingle transaction.Bidde rs may

submi tatt he auction bids thatdiffer from theones

providedinitially. If bidding in excess of theirinitial

bid, bidders maybea sked to provide additional proof

of financial ability to make such bid asacondition to

winning the auction. All amounts received on account

of the auction sale willbe applie dtothe indebtedness

ofBellum.

Please be advised that the Secured Party reservesthe

right to credit bid the indebtedness of Bellum to The

Credit Junction in the aggregate amount of at least

$10,000,000andtopostponethesalefromtimetotime

as ann ouncedorall yonorp rior to the date ofthe

auction.

Legal Notices

Legal Notices

Legal Notices

prices from U.S. drug mak-

ers.”

Trump said it was “ridic-

ulous” that “their medicine

is a tiny fraction of what the

medicine costs in the USA.”

The implication was that

people in other countries

should be paying as much as

Americans.

Now the president has

reversed course and essen-

tially said Americans should

be entitled to the same

reasonable prices that

Canadians pay.

Presumably we also

should be paying the same

as the British, French, Ger-

mans, Japanese and people

in other developed coun-

tries that actively work to

prevent pharmaceutical

price-gouging.

Azar, who last year dis-

missed drug imports as a

“gimmick,” told reporters

Wednesday that Trump has

always favored the idea,

which he hasn’t, and that

the president has been

pressuring government

officials to take action.

“He is always pushing

me, challenging me to find

more solutions to help the

American patient,” Azar

said.

The willingness of this

administration to indulge in

fantasy never fails to im-

press.

Healthcare experts I

spoke with after the admin-

istration’s announcement

said that while drug imports

from Canada could be effec-

tive, it won’t take long for

the pharmaceutical indus-

try to figure out ways to

fleece people in both coun-

tries.

“I feel sorry for the Cana-

dians,” said David Dranove,

a professor of health indus-

try management at North-

western University. “Once

borders are free, the law of

one price applies. And I

doubt whether drugmakers

will choose the Canadian

price.”

Or if they do continue

selling their products north

of the border at fair prices,

they’ll tighten supplies so

there aren’t enough drugs

left for pesky Americans to

purchase at a discount.

“Do you expect the

branded suppliers will ship

more product to Canada

than the Canadian demand

requires?” asked William

Comanor, a professor of

health policy and manage-

ment at UCLA. “Are the

companies stupid?”

Greedy, yes. Stupid, no.

“Drug manufacturers are

going to make it difficult for

Canada to subsidize our

drugs,” said Stacie B. Du-

setzina, an associate profes-

sor of health policy at Van-

derbilt University.

In fact, the industry

wasted no time in voicing its

opposition to the adminis-

tration’s plan, which at this

point has no time frame for

implementation.

Stephen J. Ubl, head of

Pharmaceutical Research

and Manufacturers of

America, an industry group,

said the proposal is “far too

dangerous for American

patients.”

“There is no way to guar-

antee the safety of drugs

that come into the country

from outside the United

States’ gold-standard sup-

ply chain,” he said. “Drugs

coming through Canada

could have originated from

anywhere in the world and

may not have undergone

stringent review by the

FDA.”

This is, of course, a bogus

argument. It’s predicated

on the idea that Canadian

officials have less-stringent

safety standards than their

U.S. counterparts, which

should be insulting to all our

friends in the Great White

North.

As James Villeneuve,

Canada’s former consul

general in Los Angeles, told

me a year ago, “Our regula-

tory standards are as high

as anything in your country.

All imported drugs are

regulated and reviewed

before reaching the public.”

What U.S. drugmakers

are worried about isn’t

endangering American

patients.

It’s endangering Ameri-

can profits.

For all his bluster about

the pharmaceutical indus-

try “getting away with

murder,” Trump has consis-

tently backed off from any

plan to lower drug prices

that would displease corpo-

rate donors.

While the industry typi-

cally plays both sides of the

political fence, it routinely

contributes more to Repub-

lican causes than Demo-

cratic.

PhRMA, the industry

group, last year spent about

$28 million on lobbying.

If Trump really wants to

show he’s serious about

lowering drug prices, he

should get behind another

core Democratic proposal

—empowering Medicare to

negotiate drug prices.

Yes, this would represent

that exact same “socialized

healthcare” that Trump and

other Republicans rail

against. But it’s also pre-

cisely why the Canadians

and others aren’t systemat-

ically swindled by drugmak-

ers.

To date, Republican

lawmakers have blocked all

attempts to unshackle

Medicare and allow it to flex

its market muscle on behalf

of its 60 million beneficia-

ries.

PhRMA’s Ubl said that

“rather than surrender the

safety of Americans by

importing failed polices

from single-payer countries,

we should work on solutions

here at home that would

lower patient out-of-pocket

costs at the pharmacy

counter.”

Because, you know,

that’s worked out really well

so far.

What we should actually

do is implement policies

that we know will work —

policies that have been

tested and perfected by our

economic peers.

Trump talks a good

game when it comes to drug

prices. But that’s all it’s

been. Talk.

Which is to say, a gim-

mick.

David Lazarus’ column runs

Tuesdays and Fridays. He

also can be seen daily on

KTLA-TV Channel 5 and

followed on Twitter

@Davidlaz. Send your tips

or feedback to david.lazarus

@latimes.com.

PRESIDENT TRUMP, with Health and Human Services Secretary Alex Azar,

wants to allow Americans to legally access prescription drugs from Canada.

Alex BrandonAssociated Press

Trump reverses course

on Canada drug pricing

[L azarus,from C1]

‘He is always

pushing me,

challenging me to

find more

solutions to help

the American

patient.’

—Alex Azar,

health and human services

secretary on President Trump

freeze.

Credit monitoring alerts

people when there are

changes in their credit re-

ports that could signal

fraudulent activity has oc-

curred. A credit freeze, in ef-

fect, blocks applications for

new credit in your name un-

til you lift the freeze, so no

one would be able to tap your

credit if your identity was

stolen.

“The right thing to do is

get a credit freeze,” said Ed

Mierzwinski, federal con-

sumer program director at

the U.S. Public Interest Re-

search Group. “Credit moni-

toring only tells you if your

credit report has changed al-

ready, maybe because you’re

a victim of identity theft. The

horse already has left the

barn.”

Ted Rossman, an analyst

with CreditCards.com,

agreed. “I would just take

whatever [cash] payout they

give” and get a credit freeze,

he said. “I don’t really value

the credit monitoring.”

Afreeze “effectively pre-

vents someone else from

opening credit in your name,

so they can’t get a new car

loan or any loan posing as

you,” Rossman said.

In addition, credit moni-

toring is free from many

sources, including credit-

card companies and sites

such as CreditKarma.com

and Bankrate.com, a sister

site to CreditCards.com.

One major bank, Capital

One, this week also reported

a data breach that affected

106 million people in the

United States and Canada,

and it’s also offering free

credit monitoring to those

people as part of its

response.

But Linda Sherry, direc-

tor of national priorities at

Consumer Action, said the

credit monitoring offer is

“the best available advice” at

this point.

She noted that with a

credit freeze, the onus is on

the consumer to freeze and

unfreeze their credit. If the

cash payout in the settle-

ment “seems paltry, why not

take the credit monitoring?”

she said. “Go ahead and

claim the $125” and then

“watch for an email from the

settlement administrator”

that provides an option to

choose credit monitoring in-

stead, she said. And make

sure to read any fine print.

“You just want to be sure

that ... you don’t waive your

legal rights in the future.”

Meanwhile, for those who

can document that they

were the victims of fraud or

identity theft tied to the

Equifax breach, up to

$20,000 in compensation is

available. That money

comes from a different pot.

Consumers weigh cash or

monitoring from Equifax

[E quifax,from C1]